TRANSLATE

Friday, 24 January 2014

DISCLOSING MEDICAL COSTS CAN HELP AVOID "FINANCIAL TOXICITY"


High costs of cancer treatments can be an “undisclosed toxicity” that can harm a patient’s overall health and well-being, according to an article in The New England Journal of Medicine.1 High medical bills can not only cause stress and anxiety but may also compel patients to cut back on spending for other basic needs—such as food, leading to less healthy diets—or to take medications less frequently than prescribed. 
“This is a very frequent cause of nonadherence,” the article’s lead author, Peter A. Ubel, MD, Professor of Business, Public Policy, and Medicine at Duke University, Durham, North Carolina, said in an interview with The ASCO Post. “It is a medical problem. Patients may not be showing up for tests or taking their pills because they can’t afford it. Dr. Ubel also tackled the issue of physicians rarely discussing medical intervention costs in an op-ed article he wrote for The New York Times.2
Not Always Easy to Know
“Because treatments can be ‘financially toxic,’ imposing out-of-pocket costs that may impair patients’ well-being, we contend that physicians need to disclose the financial consequences of treatment alternatives just as they inform patients about treatments’ side effects,” Dr. Ubel and colleagues wrote. They acknowledged that “it is very difficult, and often impossible for the clinician to know the actual out-of-pocket costs for each patient, since costs vary by intervention, insurer, location of care, choice of pharmacy or radiology service, and so on,” but added, “some general information is known.”
To those who say that they can’t disclose costs to patients because they themselves don’t know the prices, Dr. Ubel responds, “But you have an idea. For treatments you prescribe or use frequently, you have a pretty good idea. You know that some things are likely to cost your patients next to nothing and some things can cost a lot. That is a good starting point.”
While discussing costs of medical treatment would add time in an already tight schedule, Dr. Ubel challenged physicians to “think about how much time we spend trying to adjust medicines and revisit problems that we later found out occurred because patients were taking the pills every other day because they couldn’t afford them.” A recent study found that found 24% of cancer patients avoided filling prescriptions to save money, 19% partially filled prescriptions, and 20% took less than the prescribed amount of medication. In addition, 46% reduced the amount spent on food and clothing.3
Cheaper Alternatives
“Patients experience unnecessary financial distress when physicians do not inform them of alternative treatments that are less expensive but equally or nearly as effective,” Dr. Ubel and colleagues wrote in The New England Journal of Medicine. “We discovered this phenomenon when interviewing a convenience sample of breast-cancer survivors who had participated in a national study of financial burden. Many women reported discussing treatment-related costs with their physicians only after they had begun to experience financial distress.”
Physicians should be aware of these cheaper alternatives “because they used to be the main treatment before newer, more expensive ones came along,” Dr. Ubel told The ASCO Post. “They might be out of the habit of using these alternative treatments and some doctors won’t think that they are reasonable alternatives because they are no longer the ‘best’ treatment, but I just want to redefine ‘best,’ because best is what fits a patient’s goal the closest. And sometimes the patient’s goal might be to trade off a little bit of medical benefit to protect his or her financial interest.”
Determining what is best for particular patients should also factor in type and frequency of testing. “Frequent MRI and CT scan imaging to follow-up on tumor progress can all be very expensive, and awareness of those costs might make you change which tests you use or how frequently you look,” Dr. Ubel said.
‘Not Financial Counselors’
During a talk at a medical school, a medical student asked Dr. Ubel, “Am I supposed to be a financial counselor, too?” After the talk, the student went up to him and said, “If I had known this was part of medicine, I would never have become a doctor. This is not about becoming a doctor.” 
As Dr. Ubel noted, “He expressed absolute visceral distress at the thought that this would be part of what he would do.” 
Given the potential medical consequences of undisclosed financial toxicity, “I think the more we think about this as a medical topic instead of a financial topic, the better,” Dr. Ubel said. “Doctors don’t want to feel like they are financial counselors. That is why we use phrases like financial toxicity and think of it as a treatment side effect. We want people to really think about this in medical terms.”
Making It Easier to Estimate Costs
Efforts by insurance companies to develop technologies to better estimate costs, as well as price-transparency legislation passed in several states, may make it easier to avoid financial toxicity. 
“I do think that those things are on the horizon and are going to happen in the next handful of years,” Dr. Ubel said. “If patients don’t already know the prices, they will quickly be able to figure them out. I would not be surprised if some electronic medical records start routinely including cost and price information so doctors are aware of it, especially in health systems such as accountable care organizations that are trying to control costs.”
In the op-ed piece in The New York Times, Dr. Ubel stated, “The Affordable Care Act will have only a modest impact on patient exposure to health-care costs because the limits it sets on out-of-pocket costs are still high compared with most people’s resources.” Whether or not disclosure of medical costs will have an impact on medical costs, “only time will tell,” Dr. Ubel said, but at least patients would have the information needed to make informed choices. “And I would predict that more frequent discussions of cost would reduce spending,” Dr. Ubel added.
Source: ASCO post 

Saturday, 18 January 2014

SYMPTOMS OF PROSTATE CANCER


Not everyone experiences symptoms of prostate cancer. In many cases, signs of prostate cancer are first detected by a doctor during a routine check-up. Some men, however, will experience changes in urinary or sexual function that might indicate the presence of prostate cancer. These symptoms include: 
A need to urinate frequently, especially at night 
Difficulty starting urination or holding back urine 
Weak or interrupted flow of urine 
Painful or burning urination 
Difficulty in having an erection 
Painful ejaculation 
Blood in urine or semen 
Frequent pain or stiffness in the lower back, hips, or upper thighs 
Please note that these symptoms can also indicate the presence of other diseases or disorders of the prostate, such as benign prostate hypertrophy (BPH) (enlargement of the prostate) or prostatitis (inflammation of the prostate). More information about prostate cancer my book “Manual of prostate cancer” 


This manual is not intended as a substitute for professional healthcare. It is a preliminary guide to educate patients about treatment options and about the disease itself, so they will be better prepared to discuss it with their health care practitioners”

RADIOTERAPIA DEL CANCER DE PROSTATA


Durante las últimas décadas, la radiación externa ha evolucionado hasta ciertos niveles que actualmente permiten administrar una mayor dosis de radiación de forma segura. Por ejemplo, las técnicas de bidimensionales, que se usaban para planificación de la radioterapia  utilizados hasta principios de 1990, permitían una limitación de la dosis de irradiación hasta los 60 - 70 Gy (gray, unidad de radiación) debido a las toxicidades agudas y crónicas. Actualmente los médicos utilizan una terapia tridimensional (3D), que es una técnica mediante la cual se dirige las radiaciones hacia el tumor desde varios ángulos logrando que los órganos alrededor de la próstata reciban menos irradiación. La terapia de radiación 3D utiliza un programa informático para integrar imágenes obtenidas de un scanner de tomografía computarizada  (el cual enseña la anatomía interna del paciente) al sistema de planificación e irradiación del paciente. Las nuevas técnicas permiten a los médicos dar dosis más altas de radiación a la próstata y reducir la exposición a la radiación a los tejidos sanos cercanos. Esta nueva técnica de irradiación provoca pocos efectos secundarios. Más información del cáncer de próstata en mi libro “Cáncer de Próstata” (disponible como e-book en español)


 “Este manual no pretende ser un sustituto de la atención médica profesional. Es una fuente de información con datos actualizados y científicamente confirmados para educar a los pacientes sobre las opciones de tratamiento y de la enfermedad en sí. Este manual esta también dirigido a ayudar a los pacientes y sus familiares a estar mejor preparados para discutir dichos temas con sus médicos.”

Tuesday, 14 January 2014

INCIDENCE OF PROSTATE CANCER


Prostate cancer is the most frequent and second most lethal malignancy (cancerous growth) in men. Survival after prostate cancer diagnosis can often exceed a decade and fewer than 5% of men without metastatic disease (cancerous cell growth from an original site to one or more sites elsewhere in the body) at diagnosis will die from prostate cancer within the first 5 to 10 years after diagnosis. Prostate cancer is extremely common, affecting 15% of white men and 18% of African American men throughout their lifetime, and it will result in death in 3% of men in North America. The disease is comparable to breast cancer, which will affect 12% of women throughout their lifetime and cause death in 3%. More information about prostate cancer in my book “Manual of prostate cancer” 


 This manual is not intended as a substitute for professional healthcare. It is a preliminary guide to educate patients about treatment options and about the disease itself, so they will be better prepared to discuss it with their health care practitioners” 

INCIDENCIA DEL CANCER DE PROSTATA


El cáncer de próstata es el tumor maligno más frecuente y el segundo más letal (después del cáncer de pulmón) en los hombres. La supervivencia tras el diagnóstico de cáncer de próstata a menudo puede exceder una década. Menos del 5% de los hombres que al momento de su diagnóstico no presentan metástasis (expansión y crecimiento de células cancerosas de un sitio original para uno o más sitios en otros lugares en el cuerpo)  morirán de  esta enfermedad  entre  5 a 10 años después del diagnóstico. El cáncer de próstata es muy común y afecta a un 15% de los blancos y el 18% de los hombres afro-americanos. La enfermedad es comparable al cáncer de mama, que afecta al 12% de las mujeres y causa la muerte en el 3% de hombres en USA. Más información del cáncer de próstata en mi libro “Cáncer de Próstata” (disponible como e-book en español) 

Este manual no pretende ser un sustituto de la atención médica profesional. Es una fuente de información con datos actualizados y científicamente confirmados para educar a los pacientes sobre las opciones de tratamiento y de la enfermedad en sí. Este manual esta también dirigido a ayudar a los pacientes y sus familiares a estar mejor preparados para discutir dichos temas con sus médicos.”

Sunday, 12 January 2014

THE LANDSCAPE OF MEDICAL ONCOLOGY IN EUROPE THREATENED


Many large European countries may be facing a future shortage of medical oncologists without realizing it -- a situation that could have dire consequences for cancer patients, the European Society for Medical Oncology (ESMO) has warned.
At the European Cancer Congress today, researchers reported new data that looks at the projected number of medical oncologists in Europe and tries to predict if European countries will face a shortage of medical oncologists by 2020.
Medical oncologists are cancer specialists who focus on treating cancer using chemotherapy, targeted drugs and other medical therapies. They work together with surgeons, radiation oncologists and other specialists to deliver multi-disciplinary care to cancer patients.
The number of people who develop cancers in greater Europe is expected to grow to 3.4 million each year by 2020, a 20% increase from 2002. It is vital that countries increase their numbers of cancer specialists to match that growth, ESMO warns.
"There is increasing evidence demonstrating that limited access to a medical oncologist can lead to less timely access to anticancer treatments and therefore have a negative effect on outcomes," says Raffaele Califano, Chair of the ESMO Young Oncologists Committee and consultant medical oncologist at the Cancer Research UK Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester.
The new data reported at the conference show that adequate data on the projected numbers of medical oncologists was only available for 12 of 27 European Union nations.
"Looking at the available data, it seems that there will not be any shortage of medical oncologists in Central European and Western European countries by 2020, but the data was not available for several countries with large populations such as the Russian Federation, Turkey, Spain, Poland and Greece," said Dr Califano.
It is also important to notice that this data is based on cancer incidence and not cancer prevalence; furthermore the current economic crisis might have an influence on the number of doctors migrating to other countries.
ESMO believes that continuous monitoring from official authorities is the only way to ensure that the ratio of new cases of cancer to medical oncologists is adequate. This data would allow specialist-training programmes to be modified and new posts for medical oncologists created to maintain adequate numbers.
"This is the only way to make sure that excellent and safe standards of care for cancer patients can be maintained," Califano said.
"We believe the next step is to endeavor to collect data from the non-surveyed countries in order to have definitive information about the expected change in number of medical oncologists across all EU countries. This will help to understand fully if Europe is ready to face the new cancer cases predicted by 2020 and appropriate resources are in place," Califano said.



Source: Science Daily